Nikkei Industry Sector
Pharmaceuticals
Overview
Japan's pharmaceutical sector includes both large domestic-focused drug makers and globally operating biopharmaceutical companies with significant international revenue. The industry combines deep scientific capability with strong regulatory relationships and a large aging domestic patient population that drives consistent baseline demand.
Current Trend
Japanese pharma companies are accelerating globalization through overseas acquisitions, licensing deals, and co-development partnerships—particularly in oncology and rare diseases. Biosimilar manufacturing, leveraging Japan's precision production expertise, is also emerging as a significant growth opportunity as biologic patents expire globally.
Companies in This Sector
9
Today's Avg. Price Change
+1.39%
Simple average of constituent stock price changes vs. previous close. Not a sector index.
Updated: 2026-10-30 (JST)
Position in Japan
Japan is the world's third-largest pharmaceutical market by value, providing a stable and substantial home base. The National Health Insurance system, while exerting downward pricing pressure through biennial drug price revisions, ensures broad market access for approved therapies and a predictable revenue floor.
Latest Press Releases
17
Sep
Otsuka Holdings Co.,Ltd. JP3188220002
2026-09-16 Otsuka Holdings Co.,Ltd. “EN Otsuka Pharmaceutical has obtained manufacturing and marketing approval for its enteral nutrition formula, "Innofeed® Enteral Solution."”
17
Sep
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-09-16 DAIICHI SANKYO COMPANY,LIMITED “Notice of two partial amendments to the approval of the anti-cancer drugs "Enhertu®" and "Datroway®" for the first-line treatment of metastatic breast cancer in Japan (257.4KB) PDF file will be displayed in a new window.”
17
Sep
Eisai Co.,Ltd. JP3160400002
2026-09-16 Eisai Co.,Ltd. “Rekenbi®, a subcutaneous injection formulation of the early-stage Alzheimer's disease treatment drug Rekenbi®, has received approval in Japan—the first and only home-administered anti-amyloid therapy for Alzheimer's disease in Japan.”
17
Sep
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-09-16 CHUGAI PHARMACEUTICAL CO.,LTD. “FoundationOne CDx cancer genome profiling has been approved as a companion diagnostic for tovorafenib in gliomas positive for BRAF V600 mutations and BRAF fusion genes.”
17
Sep
Shionogi & Co.,Ltd. JP3347200002
2026-09-16 Shionogi & Co.,Ltd. “Regarding the acquisition of manufacturing and marketing approval for the addition of dosage and administration instructions for "Vitamer® Cream" in Japan for the treatment of atopic dermatitis in children (under 12 years of age).”
17
Sep
Shionogi & Co.,Ltd. JP3347200002
2026-09-16 Shionogi & Co.,Ltd. “Regarding the acquisition of partial approval in Japan for the Omicron strain JN.1 recombinant protein vaccine "CovGoze® Intramuscular Injection" for COVID-19.”
15
Sep
Otsuka Holdings Co.,Ltd. JP3188220002
2026-09-14 Otsuka Holdings Co.,Ltd. “In the Phase III REZILIENT3 trial for first-line treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations, the combination of diparereltinib and chemotherapy extended the median progression-free survival by 6 months.”
15
Sep
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-09-14 DAIICHI SANKYO COMPANY,LIMITED “The latest data from the Phase 3 clinical trial of trastuzumab deruxtecan (T-DXd/DS-8201) for first-line treatment of non-small cell lung cancer with HER2 gene mutations, presented at the World Conference on Lung Cancer (WCLC 2026), will be displayed in a new window as a PDF file (282.8KB).”
15
Sep
Eisai Co.,Ltd. JP3160400002
2026-09-14 Eisai Co.,Ltd. “We have concluded an agreement with Osaka Prefecture regarding cooperation and collaboration in raising awareness of dementia and MCI (mild cognitive impairment).”
11
Sep
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-09-10 DAIICHI SANKYO COMPANY,LIMITED “The PDF file (159.1KB) regarding the judgment (in favor of our company) in the lawsuit filed by NTK against our company for damages will be displayed in a new window.”
11
Sep
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-09-10 CHUGAI PHARMACEUTICAL CO.,LTD. “Roche's announcement regarding Enspryng (FDA acceptance of application and priority review designation for MOG antibody-related disease).”
11
Sep
Shionogi & Co.,Ltd. JP3347200002
2026-09-10 Shionogi & Co.,Ltd. “Regarding my presentation at Infectious Diseases Association Week (IDWeek 2026).”
10
Sep
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-09-09 CHUGAI PHARMACEUTICAL CO.,LTD. “Three researchers from Chugai Pharmaceutical, who created Hemlibra, a treatment for hemophilia A, have been awarded the prestigious Lasker Award, a globally recognized scientific prize in the United States. Their invention of bispecific antibodies, which revolutionized treatment through their unique approach, was recognized.”
10
Sep
Shionogi & Co.,Ltd. JP3347200002
2026-09-09 Shionogi & Co.,Ltd. “Preliminary report on the results of clinical trials of the regenerative medicine development product, Ledasemutide, in patients with dystrophic epidermolysis bullosa and acute ischemic stroke.”
09
Sep
Kyowa Kirin Co.,Ltd. JP3256000005
2026-09-08 Kyowa Kirin Co.,Ltd. “Announcement regarding the top-line data report of the Phase 2 international clinical trial of KHK4951, a VEGF receptor-targeted eye drop under development for neovascular age-related macular degeneration (763KB).”
08
Sep
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-09-07 CHUGAI PHARMACEUTICAL CO.,LTD. “Chugai Pharmaceutical's research findings on nemolizumab received the 11th JBDA Drug Discovery Award.”
08
Sep
Shionogi & Co.,Ltd. JP3347200002
2026-09-07 Shionogi & Co.,Ltd. “Regarding the approval of cefiderocol, a drug for treating Gram-negative bacterial infections, in Australia.”
04
Sep
Eisai Co.,Ltd. JP3160400002
2026-09-03 Eisai Co.,Ltd. “Rekenbi®, a subcutaneous injection formulation, has received approval in China as an initial treatment for early-stage Alzheimer's disease—the first and only home-administered anti-amyloid therapy for Alzheimer's disease, a progressive neurodegenerative disease, in China.”
02
Sep
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-09-01 DAIICHI SANKYO COMPANY,LIMITED “Notice of Partial Approval for the EU Regarding the First-Line Treatment of HER2-Positive Breast Cancer with Enhertu® (trastuzumab deruxtecan) and Pertuzumab (224.4KB) PDF file will open in a new window.”
02
Sep
Eisai Co.,Ltd. JP3160400002
2026-09-01 Eisai Co.,Ltd. “The Canadian Medicines Agency has published its final recommendation supporting public reimbursement for the early-stage Alzheimer's disease treatment Lekenbi® (lecanemab)—a significant step towards expanding access to Lekenbi for eligible individuals in Canada.”